After slow start, demand for COVID monoclonal antibodies treatment skyrockets https://www.usatoday.com/story/news/health/2021/08/25/monoclonal-antibodies-treatment-demand-skyrockets-covid-cases-climb/5579505001/
1 « J'aime »
Je sais que nous sommes dans l’univers du microcap mais quelqu’un a regardé Regeneron ? Il me semble beaucoup mieux positionné que IPA. Et est déjà très rentable !
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
The Company to host an earnings conference call via webcast on September 9, 2021, at the close of market
VICTORIA, BRITISH COLUMBIA September 3, 2021 / - IMMUNOPRECISE ANTIBODIES LTD. (the « Company » or « IPA ») (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a conference call to discuss its financial results and recent business highlights for first quarter fiscal year 2022, on September 9, 2021, after the close of market. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. Investors interested in submitting questions ahead of the call are encouraged to email the Company’s investor relations representative.
Conference Call:
Date: September 9, 2021
Time: 4:30 p.m. Eastern time
Toll-free dial-in number: 1-877-407-3982
International dial-in number: 1-201-493-6780
Conference ID: 13722893
Webcast: http://public.viavid.com/index.php?id=146463
The conference call will be webcast live and available for replay via a link provided in the Events section of the company’s IR pages at https://www.immunoprecise.com/investors.
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.
Anyone listening to the call is encouraged to read the company’s periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit www.immunoprecise.com.
Investor contact:
LifeSci Advisors
John Mullaly Email: jmullaly@lifesciadvisors.com
We seek Safe Harbor.
Biden administration unveils $65 billion plan to combat next pandemics after Covid
“The U.S. would spend a total of $24.2 billion to develop and test new vaccines for a range of viruses and make improvements to vaccine distribution and manufacturing.
The plan also calls for spending $11.8 billion on therapeutics, which would allow U.S. scientists and drugmakers develop new antivirals and other drugs and ensure large-scale manufacturing capacity for monoclonal antibody treatments. ”
2 « J'aime »
Il prend du temps le coup de téléphone 
Désolé… j’ai pas pu m’empêcher quand j’ai revu ce post!
2 « J'aime »
Semble une méchante bonne nouvelle! Will see!
ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
VICTORIA, British Columbia, October 13, 2021, - IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced that it has entered into an At-The-Market Distribution Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as sole sales agent (the “Agent”). Under the ATM Agreement, the Company will be entitled, at its discretion and from time-to-time during the term of the ATM Agreement, to sell, through the Agent common shares of the Company (the “Common Shares”) having an aggregate gross sales price of up to US$50 million (the “Offering” or “ATM Facility”). Sales of the Common Shares will be made in transactions that are deemed to be “at-the-market offerings” as defined in Rule 415 of the United States Securities Act of 1933, as amended, and “at-the-market distributions” as defined in National Instrument 44-102 – Shelf Distributions , including, without limitation, sales made directly on the Nasdaq Global Market or any other existing trading market for the Common Shares in the United States. No offers or sales of Common Shares will be made in Canada on the TSX Venture Exchange (the “TSXV”) or other trading markets in Canada.
The Company will determine, at its sole discretion, the date, minimum price and maximum number of Common Shares to be sold under the ATM Facility. The Common Shares will be distributed from time to time in negotiated transactions, at market prices prevailing at the time of sale, at prices relating to such prevailing market prices, and/or in any other manner permitted by applicable law. As such, the prices may vary between purchasers over time. The Company is not required to sell any Common Shares at any time during the term of the ATM Facility.
The Company intends to use the net proceeds of the Offering, if any and at the discretion of the Company, to support the growth and development of the Company’s existing operations as well as working capital and general corporate purposes. The Company will pay the Agent a cash fee for Common Shares sold under the ATM Agreement and will reimburse certain expenses incurred by the Agent.
The TSXV has conditionally approved the listing of the Common Shares distributed in the Offering, and the Nasdaq Global Market has been notified of the Offering.
The Offering will be made by way of a prospectus supplement dated October 13, 2021 (the “Prospectus Supplement”) to the Company’s existing Canadian short form base shelf prospectus dated December 11, 2020 (the “Base Shelf Prospectus”) and U.S. registration statement on Form F-10, as amended (File No. 333-249957), dated January 5, 2021 (the “Registration Statement”). The Registration Statement was declared effective by the United States Securities and Exchange Commission (the “SEC”) on January 11, 2021. The Prospectus Supplement has been filed with the British Columbia Securities Commission and the SEC. The ATM Agreement, the Prospectus Supplement and the related Base Shelf Prospectus are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Alternatively, the Agent will send the documents upon request by contacting the Agent: H.C. Wainwright & Co., LLC, 430 Park Avenue 3rd Floor, New York, NY 10022, telephone: (646) 975-6996, email: placements@hcwco.com. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
We seek Safe Harbor.
Target à 12$ US pour IPA et recommandation d’achat!
Paul démissionne de son poste de directeur!
Je ne sais pas trop quoi penser de ça… j’espère qu’il va s’expliquer sur son forum SCD
IPA ANNOUNCES RESIGNATION OF DIRECTOR
Paul Andreola, a member of the board of directors of Immunoprecise Antibodies Ltd., has resigned, effective immediately, from the company’s board of directors for personal reasons unrelated to the company.
« On behalf of the company and the board of directors, I would like to thank Paul for serving on our board of directors. His insightful and experienced contributions were highly valued, and we wish Paul all the best in his future endeavours, » commented Jennifer Bath, president and chief executive officer, and director of the company.
Mr. Andreola commented: « It has been a privilege to serve on the board since 2018. I leave the company with great optimism in its leadership and strategy, and will continue to support IPA from the sidelines as an engaged shareholder. »
As a result of Mr. Andreola’s resignation, Mr. Andreola will no longer stand for re-election at the company’s upcoming annual general meeting of shareholders.
Twist nabs antibody discovery biotech Abveris for $190M a week after spinning out COVID unit
Revenu annuel de 4.1M pour Abveris avec seulement 21 employés selon Abveris Inc - $4.1 Million Revenue | KonaEquity.com
1 « J'aime »
ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program
IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) is providing an update on its Polytope™ Development Program. The Company continues to rapidly progress it SARS-CoV-2 multi-antibody cocktail therapy, PolytopeTM, and has met the following milestones:
U.S. Food and Drug Administration assessed IPA’s pre-investigational new drug application; preclinical safety studies have now commenced as previously scheduled.
IPA drafted a pre-investigational new drug (PIND) application and received feedback from the U.S. Food and Drug Administration (FDA). IND-enabling studies have now commenced on schedule with initial IND-enabling data from the studies still expected by the end of 2021. The feedback from the FDA on the PIND file is crucial in preparation for the potential submission to the FDA of a full IND-application, which must be approved by the FDA prior to commencing first-in-human clinical studies.
SARS-CoV-2 PolyTope™ antibody cocktail retains binding efficacy against viral variants-of-concern tested in pre-clinical studies
As stated in prior announcements by IPA, the PolyTope™ strategy is to sustainably combat SARS-CoV-2 and emerging variants, which have the potential to escape protective antibodies via mutations in their antibody-targeted spike protein. IPA’s therapeutic multi-antibody cocktail continues to demonstrate binding to spike proteins of all novel viral variants tested by IPA to date. Recent studies confirm that the PolyTope™ antibody mixture is also resilient to WHO-designated variants-of-concern Lambda (C.37) and Mu (B.1.621). The Company continues to track efficacy of its proprietary antibodies against a number of novel amino acid mutations from emerging variants-of-concern (VoC) designated by WHO.
As with previous variants, IPA has already begun analysing the recent Omicron variant (B.1.1.529) to assess retention of binding to cell associated Omicron spike protein variant.
Protein homogeneity in PolyTope™ antibody cocktail for production purposes has improved
The quality of future clinical production batches was significantly advanced by successful single amino acid substitutions in the variable region of two constituents in the PolyTope™ antibody mixture. Expression of the modified protein backbones yields antibodies resistant to non-functional post-translational modifications. This adaptation will prevent so-called microheterogeneity and is expected to increase the quality and yield of future clinical production batches. The unaltered efficacy of the adjusted antibodies was demonstrated in in vitro virus neutralization experiments and in in vivo experiments involving virus-challenged hamsters.
“Our Polytope program continues to exceed internal expectations and we are cautiously optimistic that it will continue to prove effective against all emerging variants, in particular as our Polytope was conceived with this specific purpose in mind,” stated Dr. Jennifer Bath, IPA CEO and President. “IPA is fully aware of the global importance of the continued advancement of its proprietary cocktail therapy, and we are happy to share the program remains on track.” Dr. Bath added, “FDA feedback on our pre-IND application was very helpful as we entered our pharmacokinetic and toxicological studies and as we continue on our quest to provide a best-in-class COVID therapy.”
In conclusion, IPA has engineered a blend of what the Company believes to be highly active anti-SARS-CoV-2 antibodies comprising a potential COVID-19 therapeutic which have demonstrated in vitro and in vivo efficacy in pre-clinical studies conducted to date against a number of variants of concern. In those studies, the PolyTope therapeutic has not only shown synergistic activity, but also resilience towards viral mutants. Following discussions with the FDA on IPA’s PIND, the PolyTope™ cocktail has entered PIND studies beginning with the determination of acute toxicity in dose-escalation experiments. The PIND studies are expected to end with final toxicology evaluations in January 2022 when the pharmacokinetic analyses, which are planned to commence by mid-December this year, are anticipated to have been completed.
4 « J'aime »
La société organisera une téléconférence sur les résultats via webdiffusion le 13 décembre 2021, à la clôture du marché
December 07, 2021 01:28 PM Eastern Standard Time
VICTORIA, Colombie-Britannique–(BUSINESS WIRE)–IMMUNOPRECISE ANTIBODIES LTD. (la « Société » ou « IPA ») (NASDAQ : IPA) (Bourse de croissance TSX : IPA), un leader de la découverte et du développement d’anticorps thérapeutiques à service complet, annonce une téléconférence pour discuter de ses résultats financiers et des temps forts de ses activités récentes pour le deuxième trimestre de l’exercice 2022, le 13 décembre 2021, après la clôture du marché. Les résultats financiers seront publiés dans un communiqué de presse avant la téléconférence. La direction d’ImmunoPrecise animera la téléconférence et répondra aux questions déposées au préalable.
Les investisseurs qui souhaitent soumettre des questions avant la conférence sont invités à envoyer un courriel à la personne de contact des relations avec les investisseurs.
Renseignements à propos de la téléconférence sur les résultats :
Date : 13 décembre 2021
Heure : 16h30 heure de l’EST
Numéro d’appel gratuit : 1-877-407-3982
Numéro d’appel international : 1-201-493-6780
Identifiant de la conférence : 13725499
Webdiffusion : https://viavid.webcasts.com/starthere.jsp?ei=1517703&tp_key=6a89213907
La téléconférence sera diffusée en direct sur internet et pourra être réécoutée en cliquant sur le lien fourni dans la section « Events » à l’adresse : https://www.immunoprecise.com/company/events/.
Veuillez composer le numéro de téléphone de la conférence cinq minutes avant le début. Un opérateur enregistrera votre nom et votre organisation.
Toute personne écoutant l’appel est invitée à lire les rapports périodiques de la Société déposés auprès de la Bourse de Toronto et de la Securities and Exchange Commission, notamment la discussion sur les facteurs de risque et les résultats historiques des transactions et la situation financière dans ces rapports.
Q2 Earnings Call Transcript for Seeking Alpha.
Je ne m’attendais à rien de cette conférence téléphonique. Cependant, j’ai été agréablement surpris. Il y a eu beaucoup de mises à jour sur les différents programmes qui, je pense, auraient pu faire l’objet d’un communiqué de presse.
Avec tout ce que Jennifer a dit, je pense que nous pouvons nous attendre à quelques NR dans les 6 prochaines semaines.
Enfin une annonce de partenariat pour TATX-03. Voyons voir si le marché va réagir, pour l’instant légère hausse sur un faible volume pre-market.
1 « J'aime »
